Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
Bodor JN, Patel JD, Wakelee HA, Levy BP, Borghaei H, Pellini B, Costello MR, Dowell JE, Finley G, Huang CH, Neal JW, Nieva JJ, Puri S, Socinski MA, Thomas C, Ross EA, Litwin S, Clapper ML, Treat J. Bodor JN, et al. Among authors: pellini b. Clin Lung Cancer. 2023 Nov;24(7):e242-e246. doi: 10.1016/j.cllc.2023.05.003. Epub 2023 May 11. Clin Lung Cancer. 2023. PMID: 37451930 Free PMC article. Clinical Trial.
Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management.
Chaudhuri AA, Pellini B, Pejovic N, Chauhan PS, Harris PK, Szymanski JJ, Smith ZL, Arora VK. Chaudhuri AA, et al. Among authors: pellini b. JCO Precis Oncol. 2020 Jul 15;4:PO.20.00060. doi: 10.1200/PO.20.00060. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923907 Free PMC article. Review. No abstract available.
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Pellini B, Madison RW, Childress MA, Miller ST, Gjoerup O, Cheng J, Huang RSP, Krainock M, Gupta P, Zou W, Shames DS, Moshkevich S, Ballinger M, Liu MC, Young A, Srivastava MK, Oxnard GR, Socinski MA. Pellini B, et al. Clin Cancer Res. 2023 Nov 14;29(22):4596-4605. doi: 10.1158/1078-0432.CCR-23-1578. Clin Cancer Res. 2023. PMID: 37702716 Free PMC article.
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. Le X, et al. Among authors: pellini b. J Clin Oncol. 2024 Oct 8:JCO2400533. doi: 10.1200/JCO.24.00533. Online ahead of print. J Clin Oncol. 2024. PMID: 39378386
Targeting SHP2 Signaling in Lung Cancer.
Imbody D, Arce K, Solanki HS, Haura EB, Pellini B. Imbody D, et al. Among authors: pellini b. J Thorac Oncol. 2024 Jan;19(1):18-24. doi: 10.1016/j.jtho.2023.08.009. Epub 2023 Aug 11. J Thorac Oncol. 2024. PMID: 37574134 Review. No abstract available.
29 results